# (CBDRA60) to Prevent or Reduce Symptoms of COVID-19 and Prevention of Post-Acute Sequelae of SARS-CoV-2 Infection PASC

> **NCT04777981** · NA · UNKNOWN · sponsor: **Anewsha Therapeutics Inc.** · enrollment: 60 (estimated)

## Conditions studied

- COVID-19
- SAR

## Interventions

- **DIETARY_SUPPLEMENT:** CBDRA60 supplement
- **DIETARY_SUPPLEMENT:** Placebo

## Key facts

- **NCT ID:** NCT04777981
- **Lead sponsor:** Anewsha Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-07-01
- **Primary completion:** 2022-12-05
- **Final completion:** 2022-12-28
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2022-02-22

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04777981

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04777981, "(CBDRA60) to Prevent or Reduce Symptoms of COVID-19 and Prevention of Post-Acute Sequelae of SARS-CoV-2 Infection PASC". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04777981. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*